Skip to main content

Table 1 Clinical characteristics of 170 patients with AL-CA in this study

From: A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China

  AL-CA (n = 170)
Male, n (%) 120 (70.59%)
Age at diagnosis, years 60.81 (10.46)
Previous misdiagnosis, n (%) 56 (32.9%)
Patients of referred, n (%) 92 (54.1%)
Length of hospital stay, days 15.94 (9.35)
First chief complaint, n (%)
Dyspnea 90 (52.94%)
Edema in lower limbs 38 (22.35%)
Fatigue 14 (8.24%)
Others 28 (16.47%)
Department of first diagnosis, n (%)
Cardiology 110 (64.71%)
Nephrology 24 (14.12%)
Hematology 20 (11.76%)
Others 16 (9.41%)
NYHA, n (%)
I 7 (4.12%)
II 33 (19.41%)
III 74 (43.53%)
IV 56 (32.94%)
Mayo AL 2004 stage, n (%)
I 6(4.0%)
II 38(25.3%)
IIIa 51(34%)
IIIb 55(36.7%)
Comorbidities, n (%)
Multiple myeloma 58 (34.12%)
Polyserositis 115 (67.65%)
CHD 35(20.59%)
Subclinical or clinical hypothyroidism 44 (25.88%)
Peripheral neuropathy 46(27.1%)
Previous hypertension 58 (34.12%)
Hyperlipidemia 41 (24.12%)
Type 2 diabetes 22 (12.94%)
COPD 19 (11.18%)
CKD 56 (32.94%)
Stroke 12 (7.06%)
SBP, mmHg 114.23 (24.18)
DBP, mmHg 71.18 (12.50)
Pulse, Times/min 82.41 (17.82)
BMI, kg /m2 22.5 (3.5)
Death in hospital, n (%) 21 (12.4%)
Assistant examination methods, n (%)
Non-invasive, n (%)  
CMR 88 (51.7%)
SPECT 17 (10.0%)
Biopsy, n (%)
Endocardial 21 (12.3%)
Bone marrow 134(78.9%)
Renal 13(7.6%)
Subcutaneous fat 89(52.4%)
Gastrointestinal 7(4.1%)
Othersa 2(1.2%)
Treatment
Pacemaker 14 (8.2%)
ACEI/ARB 40 (23.5%)
Beta-blockers 35 (20.6%)
Loop diuretics 154 (90.6%)
Antisterone 127 (74.7%)
Tolvaptan 15 (8.8%)
LMWH 29 (17.1%)
Warfarin 12 (7.1%)
Digitalis 32 (18.8%)
Aspirin 38 (22.4%)
Clopidogrel 28 (16.5%)
Statins 62 (36.5%)
Chemotherapy, n (%) 64 (37.6%)
B + D 39 (22.9%)
Melphalan-based 7 (4.1%)
ThD/LeD 56 (32.9%)
ASCT 2(1.2%)
Palliative care, n (%) 106(62.4%)
  1. Date are shown as (N) Mean (SD) or n (percentage)
  2. NYHA: New York heart association functional classification; CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index. ECG: electrocardiographic; CMR: cardiac magnetic resonance; LMWH: low molecular weight heparin; B + D: bortezomib + dexamethasone, ASCT: autologous stem cell transplantation; ThD/LeD: thalidomide/lenalidomide
  3. aTongue biopsy was performed in 2 patients with AL-CA